Protalix BioTherapeutics Inc. (NYSE:PLX) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.

According to Zacks, “Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix’s unique expression system presents a proprietary method for developing recombinant proteins in a cost-effective, industrial-scale manner. Protalix’s first product manufactured by ProCellEx, taliglucerase alfa, was approved for marketing by the U.S. Food and Drug Administration (FDA) in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights. “

A number of other analysts have also recently commented on PLX. Rodman & Renshaw reissued a “buy” rating on shares of Protalix BioTherapeutics in a research report on Monday, July 11th. Jefferies Group lowered their price objective on Protalix BioTherapeutics from $1.75 to $0.80 and set a “buy” rating on the stock in a research report on Tuesday, September 6th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Protalix BioTherapeutics (NYSE:PLX) opened at 0.6004 on Wednesday. The stock has a 50 day moving average price of $0.62 and a 200-day moving average price of $0.74. Protalix BioTherapeutics has a 12-month low of $0.58 and a 12-month high of $1.44. The company has a market capitalization of $59.89 million and a price-to-earnings ratio of 1.1866.

Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings results on Monday, August 8th. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by $0.03. The firm earned $1.77 million during the quarter, compared to analysts’ expectations of $1.34 million. During the same quarter in the prior year, the company posted ($0.05) earnings per share. Equities analysts predict that Protalix BioTherapeutics will post ($0.41) EPS for the current fiscal year.

About Protalix BioTherapeutics

5 Day Chart for NYSE:PLX

Receive News & Ratings for Protalix BioTherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protalix BioTherapeutics Inc. and related companies with's FREE daily email newsletter.